pbf-999
Small moleculeexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT02208934)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Adenosine A2a receptorANTAGONIST
ADORA2A antagonist
- Phosphodiesterase 10AINHIBITOR
PDE10A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C#CCNc1nc(-n2cncn2)nc(N)c1Br- Mol. weight
- 294.12 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3942498 ↗
- ChEMBLCHEMBL3545271 ↗
Also known as
- pbf-999
- pbf-999
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03786484 | Phase 1 | Oct 1, 2017 | Paloma Pharmaceuticals, Inc., Vall d'Hebron Institute of Research, Galatea Clinic |
| NCT02907294 | Phase 1 | Mar 1, 2016 | CIM Sant Pau, Paloma Pharmaceuticals, Inc., University of Barcelona |
| NCT02208934 | Phase 1 | Sep 1, 2014 | CIM Sant Pau, Palo Biofarma, S.L, University of Barcelona |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CIM Sant Pau | Academic/Hospital | 2 | 0 | 1 | 2014 |
| Paloma Pharmaceuticals, Inc. | For profit | 2 | 2 | 1 | 2016 |
| University of Barcelona | Academic/Hospital | 2 | 1 | 1 | 2014 |
| Palo Biofarma, S.L | For profit | 1 | 0 | 1 | 2014 |
| Vall d'Hebron Institute of Research, Galatea Clinic | Academic/Hospital | 1 | 0 | 1 | 2017 |
5 organizations
Page 1 / 1